A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
Clinical trial NCT07069335 · RECRUITING
Trial details
- NCT number
- NCT07069335
- Sponsor
- Boryung Pharmaceutical Co., Ltd
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-17
- Primary completion
- 2026-05-15
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.